CN111285900B - 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途 - Google Patents
基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途 Download PDFInfo
- Publication number
- CN111285900B CN111285900B CN202010116358.6A CN202010116358A CN111285900B CN 111285900 B CN111285900 B CN 111285900B CN 202010116358 A CN202010116358 A CN 202010116358A CN 111285900 B CN111285900 B CN 111285900B
- Authority
- CN
- China
- Prior art keywords
- cancer
- compound
- dcz0847
- cells
- multiple myeloma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 title description 4
- 229930188866 apocynin Natural products 0.000 title description 2
- 230000008878 coupling Effects 0.000 title description 2
- 238000010168 coupling process Methods 0.000 title description 2
- 238000005859 coupling reaction Methods 0.000 title description 2
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 title description 2
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 title description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 27
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 25
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 15
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 15
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims abstract description 15
- 229960001467 bortezomib Drugs 0.000 claims abstract description 15
- 201000005202 lung cancer Diseases 0.000 claims abstract description 15
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 15
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 14
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 14
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 14
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 13
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 13
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 13
- 201000008968 osteosarcoma Diseases 0.000 claims abstract description 13
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 13
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 13
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 12
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 11
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 10
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 10
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 39
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 229940125782 compound 2 Drugs 0.000 claims description 3
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- XZVLBRUSPGFZMX-UHFFFAOYSA-N 1-n,2-n-dimethyl-2h-pyridine-1,2-diamine Chemical compound CNC1C=CC=CN1NC XZVLBRUSPGFZMX-UHFFFAOYSA-N 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 68
- 238000002474 experimental method Methods 0.000 abstract description 12
- 230000002147 killing effect Effects 0.000 abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 3
- 206010059866 Drug resistance Diseases 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000010261 cell growth Effects 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000011580 nude mouse model Methods 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 7
- 101710188750 COUP transcription factor 2 Proteins 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101100481912 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) tpc-1 gene Proteins 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 150000007522 mineralic acids Chemical class 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- -1 etc.) Polymers 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000001099 axilla Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VEVBDJJJDCSTSG-UHFFFAOYSA-N Cl.P(=O)(OC1=C(C=C(C=C1)C(C)=O)OC)(OC1=CC=C(C=C1)C=CC1=CC(=CC(=C1)OC)OC)ON1CCN(CC1)C Chemical compound Cl.P(=O)(OC1=C(C=C(C=C1)C(C)=O)OC)(OC1=CC=C(C=C1)C=CC1=CC(=CC(=C1)OC)OC)ON1CCN(CC1)C VEVBDJJJDCSTSG-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- OOXWYYGXTJLWHA-UHFFFAOYSA-N cyclopropene Chemical compound C1C=C1 OOXWYYGXTJLWHA-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种抗肿瘤化合物DCZ0847及其制备方法和应用，所述化合物结构式如下所示。本发明还提供了所述化合物的制备方法，该方法具有步骤简单、得率高的优点。细胞实验显示，化合物DCZ0847对多发性骨髓瘤、淋巴瘤、甲状腺癌、肺癌、膀胱癌、胃癌、结肠癌细胞、食管癌和骨肉瘤具有很强的杀伤活性，可通过抑制肿瘤细胞的增殖，达到预防和***的目的。DCZ0847单用或与硼替佐米联用能够有效抑制体内多发性骨髓瘤细胞生长。因此，本发明的DCZ0847小分子化合物，副作用相对较少，在抗肿瘤药物领域具有很好的应用前景。本发明不仅为抗肿瘤提供了新的治疗药物，也为克服肿瘤的耐药性提供了新途径。
Description
技术领域
本发明涉及生物医药技术领域，具体地说，是一种新型抗肿瘤化合物DCZ0847及其制备方法和应用。
背景技术
恶性肿瘤作为全球较大的公共卫生问题之一，极大地危害人类的健康，并成为新世纪人类的第一杀手。恶性肿瘤已不再只是发达工业国家的严重疾病，发展中国家面临着更大的疾病负担。恶性肿瘤包括实体瘤(如肺癌、结直肠癌、肝癌、胃癌等)和血液肿瘤(如骨髓瘤、淋巴瘤等)，两者疾病的发生发展和治疗方式有着较为显著的不同，胃癌、膀胱癌、甲状腺癌、肺癌、结肠癌、骨肉瘤是较为常见的肿瘤类型。
化学药物作为***的重要手段之一，在近三十年已经有了巨大的发展和进步，得到了一大批具有不同作用机制的临床抗肿瘤药物。但抗肿瘤药存在许多不良反应，比如脱发，呕吐，快速产生耐药性等等，这些都导致化学药物无法达到预期的治疗效果。因此，新的抗肿瘤药物的研究与开发是目前药学领域的热点和难点问题之一。发明人前期发表了多项抗肿瘤化合物相关专利，如发明专利CN201810132882.5，公开一种抗肿瘤化合物2-(4-(吡啶-4-亚甲基)苯基)-4,4a,5,5a,6,6a-六氢-4,6-乙桥环丙烯并[f]异吲哚-1,3(2H,3aH)-二酮，该化合物对多发性骨髓瘤细胞及其他肿瘤细胞(包括人淋巴瘤、肺癌、***癌和结直肠癌)具有杀伤活性。发明专利CN201610094005.4，公开了一种抗肿瘤化合物7-((4-(吡啶-4-亚甲基)苯基)氨基甲酰基)三环[3.2.2.02,4]壬-8-烯-6-甲酸，该化合物可显著抑制多发性骨髓瘤和淋巴瘤。这些已经公开的化合物对血液肿瘤(如骨髓瘤、淋巴瘤等)具有较强的杀伤活性，然而对于实体瘤(如膀胱癌、肺癌、结直肠癌、甲状腺癌、胃癌、骨肉瘤等)杀伤活性不强。
发明内容
本发明的第一个目的是针对现有技术中的不足，提供一种抗肿瘤的化合物及其制备方法和应用。
在本发明的第一方面，提供了一种抗肿瘤化合物(DCZ0847)，其化学结构式为：
在本发明的第二方面，提供了所述化合物DCZ0847的晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药。
在本发明的第三方面，提供了一种药物组合物，所述药物组合物含有药学上可接受的赋形剂或载体，以及所述化合物DCZ0847或所述化合物DCZ0847的晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药。
在本发明的第四方面，提供了所述化合物DCZ0847的制备方法，包括以下步骤：
1)三氯氧磷溶于二氯甲烷，加入化合物1和三乙胺的二氯甲烷溶液，搅拌反应完全；2)反应液加入N-甲基哌嗪3和三乙胺的二氯甲烷溶液，搅拌反应完全；3)反应液加入化合物2、N,N-二甲胺基吡啶和三乙胺的二氯甲烷溶液，搅拌反应完全；4)加入水稀释，萃取，分离，水洗，饱和氯化钠洗，干燥，蒸干，硅胶柱分离，无色油状液体，加过量盐酸***溶解混匀，蒸干，既得目标化合物。
在本发明的第五方面，提供了所述化合物DCZ0847，或所述化合物DCZ0847的晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药的用途。
作为一个优选例，提供了所述化合物DCZ0847，或所述化合物DCZ0847的晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药在制备药物中的应用，所述药物用于抗肿瘤。所述肿瘤为甲状腺癌、肺癌、膀胱癌、胃癌、结肠癌细胞、食管癌或骨肉瘤，但不仅限于此。
作为一个优选例，提供了所述化合物DCZ0847，或所述化合物DCZ0847的晶型、药学上可接受的无机酸盐或有机酸盐、水合物、溶剂合物或前药在制备试剂中的应用，所述试剂用于抑制肿瘤细胞的增殖。所述肿瘤为多发性骨髓瘤、淋巴瘤、甲状腺癌、肺癌、膀胱癌、胃癌、结肠癌细胞、食管癌和骨肉瘤，但不仅限于此。
在本发明的第六方面，提供了治疗多发性骨髓瘤药物组合物，包含化合物DCZ0847和硼替佐米，所述的DCZ0847和硼替佐米质量比为10:1。用于抑制肿瘤细胞的增殖，所述的肿瘤为多发性骨髓瘤。
本发明优点在于：
1、本发明合成了一种新型抗肿瘤化合物DCZ0847。
2、本发明的化合物DCZ0847合成方法步骤简单，得率高。
3、本发明证实了化合物DCZ0847具有很强的抗肿瘤活性，尤其对甲状腺癌、肺癌、膀胱癌、胃癌、结肠癌细胞、食管癌、骨肉瘤等实体瘤以及多发性骨髓瘤、淋巴瘤等血液***恶性肿瘤杀伤活性很强。
附图说明
附图1为本发明化合物结构示意图。
附图2-8为本发明化合物DCZ0847对甲状腺癌(TPC-1细胞)、肺癌(A549细胞)、膀胱癌(T24细胞)、胃癌(SGC-7901细胞)、结肠癌细胞(HCT116细胞)、食管癌细胞(EC109细胞)、骨肉瘤细胞(U20S细胞)的抑制曲线。图中横坐标为化合物浓度(μM)，纵坐标为相对存活率(％)。
附图9-10为本发明化合物DCZ0847针对多发性骨髓瘤的动物实验结果。其中：图9DCZ0847抑制裸鼠多发性骨髓瘤的生长。图10DCZ0847与硼替佐米联用抑制裸鼠多发性骨髓瘤的生长。
具体实施方式
本文中，“前药”是指一个试剂在体内转化为原型药。前药通常是有用的，因为在某种情况下，它们可能比原型药容易给药。前药通常是药的前体，接下来的给药和吸收被转化为活性物质，或通过一些过程变为活性更强的种类，如通过代谢途径转化。一些前药具有的化学基团使其活性较低和/或对比原型药的溶解性或一些其它性质有所改变。一旦前药的化学基团被去除和/或对其修饰，得到活性药。
所述药物组合物可以是固体形式或是液体形式，其剂型可以是片剂、分散片、含片、口崩片、缓释片、胶囊剂、软胶囊剂、滴丸、颗粒剂、注射剂、粉针剂或气雾剂等。当本发明化合物用于上述用途时，可与一种或多种药学上可接受的载体或赋形剂混合，如溶剂、稀释剂等，而且可以用如下形式口服给药：片剂、丸剂、胶囊、可分散的粉末、颗粒或悬浮液(含有如约0.05-5％悬浮剂)、糖浆(含有如约10-50％糖)、和酏剂(含有约20-50％乙醇)，或以外用方式给药：软膏剂、凝胶、含药胶布等，或者以无菌可注射溶液或悬浮液形式(在等渗介质中含有约0.05-5％悬浮剂)进行非肠胃给药。例如，这些药物制剂可含有与载体混合的约0.01-99％，更佳地约为0.1-90％(重量)的活性成分。适合的给药途径包括但不限于口服、静脉注射、直肠、气雾剂、非肠道给药、眼部给药、肺部给药、经皮给药、***给药、耳道给药、鼻腔给药及局部给药。
“药学上可接受的载体”指的是：一种或多种相容性固体或液体填料或凝胶物质，它们适合人使用，而且必须有足够的纯度和足够低的毒性。“相容性”在此指代是组合物中各组份能和本发明的化合物以及它们之间相互掺和，而不明显降低化合物的疗效。药学上可接受的载体部分例子有糖(如葡萄糖、蔗糖、乳糖等)，淀粉(如玉米淀粉、马铃薯淀粉等)，纤维素及其衍生物(如羧甲基纤维素钠、乙基纤维素钠、纤维素乙酸酯等)，明胶，滑石粉，固体润滑剂(如硬脂酸钠、硬脂酸镁)，硫酸钙，植物油(如豆油、芝麻油、花生油、橄榄油等)，多元醇(如丙二醇、甘油、甘露醇、山梨醇等)，乳化剂(如吐温类)、润湿剂(如十二烷基磺酸钠)，着色剂，调味剂，稳定剂，抗氧化剂，防腐剂，无热原水等。
下面结合具体实施方式，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解，在阅读了本发明记载的内容之后，本领域技术人员可以对本发明作各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1 化合物DCZ0847的制备
合成反应路线如下：
具体制备方法为：三氯氧磷(0.50mL,5.5mmol)溶于二氯甲烷(60mL)，氮气保护，冰浴降温，逐滴加入化合物1(1.28g,5.0mmol)和三乙胺(0.85mL,6.0mmol)的二氯甲烷(15mL)溶液，搅拌反应2小时，取样监测反应完全。反应液再次冰浴降温，然后加入N-甲基哌嗪3(0.55mL,5.0mmol)和三乙胺(0.85mL,6.0mmol)的二氯甲烷(10mL)溶液，搅拌反应5小时，取样监测反应完全。反应液再次冰浴降温，逐滴加入化合物2(830mg,5.0mmol)、N,N-二甲胺基吡啶(122mg,1.0mmol)和三乙胺(0.85mL,6.0mmol)的二氯甲烷(10mL)溶液，搅拌反应10小时，取样监测反应完全。加入水稀释，二氯甲烷萃取反应液，分离有机相，水洗，饱和氯化钠洗，无水硫酸钠干燥，减压蒸干，残余物经硅胶柱分离(PE/EA＝1:1；CH2Cl2/MeOH＝20:1)，得到无色油状液体，加过量盐酸***溶解混匀，减压蒸干，得白色固体产物DCZ0847(2.3g,产率77％)。
4-乙酰基-2-甲氧基苯基(4-(3,5-二甲氧基苯乙烯基)苯基)(4-甲基哌嗪-1-基)膦酸酯盐酸盐(4-acetyl-2-methoxyphenyl(4-(3,5-dimethoxystyryl)phenyl)(4-methylpiperazin-1-yl)phosphonate hydrochloride)：
1H NMR(400MHz,Chloroform-d)δ7.61(dd,J＝2.0,1.1Hz,1H),7.57–7.42(m,4H),7.28–7.25(m,2H),7.03(q,J＝16.3Hz,2H),6.68(d,J＝2.3Hz,2H),6.42(t,J＝2.2Hz,1H),3.94(s,3H),3.85(s,6H),3.44–3.29(m,4H),2.61(s,3H),2.33(s,4H),2.26(s,3H).13C NMR(125MHz,Chloroform-d)δ196.39,160.50,138.65,134.11,133.68,128.20,127.54,127.25,121.75,120.57,120.54,120.09,120.05,110.99,104.05,99.55,76.73,55.58,54.89,54.34,54.29,45.87,44.17,25.99.HRMS(ESI)calcd for C30H36N2O7P 567.2255[M+H]+,found 567.2258[M+H]+.
实施例2 对肿瘤细胞的杀伤活性
1.实验材料
(1)细胞株：人多发性骨髓瘤细胞(OCI-MY5、ARP-1、NCI-H929)、淋巴瘤(NUDUL-1、OCI-LY8、TMD8、DB和SUDHL-4细胞)、甲状腺癌(TPC-1细胞)、肺癌(A549细胞)、膀胱癌(T24细胞)、胃癌(SGC-7901细胞)、结肠癌(HCT116细胞)、食管癌(EC109细胞)、骨肉瘤(U20S细胞)购自美国ATCC，本实验室传代保存。
(2)主要试剂：1640培养基(美国Gibco公司)，DMEM培养基(美国Gibco公司),胎牛血清(美国Gibco公司)，DCZ0847，硼替佐米(美国Sigma公司)，Cell Counting Kit-8试剂盒(CCK8，日本株式会社同仁化学研究所)。
(3)主要仪器：二氧化碳培养箱(美国Thermo Forma公司)，全自动酶标仪(Bio-TEK，Elx800)。
2.实验方法
(1)细胞培养
结肠癌(HCT116细胞)、肺癌(A549细胞)、食管癌(EC109细胞)、骨肉瘤(U20S细胞)，培养于DMEM培养基(含10％胎牛血清)。人多发性骨髓瘤细胞(OCI-MY5、ARP-1、NCI-H929)，淋巴瘤(NUDUL-1、OCI-LY8、TMD8、DB和SUDHL-4细胞)、胃癌(SGC-7901细胞)、膀胱癌(T24细胞)、甲状腺癌(TPC-1细胞)细胞培养于1640培养基(含10％胎牛血清)。
(2)CCK8试剂盒测定对各细胞的毒性
取甲状腺癌(TPC-1细胞)、肺癌(A549细胞)、膀胱癌(T24细胞)、胃癌(SGC-7901细胞)、结肠癌(HCT116细胞)、食管癌(EC109细胞)、骨肉瘤(U20S细胞)、人多发性骨髓瘤细胞(OCI-MY5、ARP-1、NCI-H929)，淋巴瘤(NUDUL-1和SUDHL-4细胞)的单细胞悬液，计数后调整细胞浓度至2×105个/mL。取96孔培养板每孔加入95μL上述细胞悬液，然后加不同浓度的用培养基配制的药物5μL，对照组加入相应体积的培养基，每组设置3个平行孔。连续培养48h，培养结束前2h，每孔加入CCK8试剂10μL，于CO2孵箱中继续培养。2h后自动酶标仪检测450nm各孔OD值。计算细胞存活率与抑制率：细胞存活率(％)＝(实验孔OD均值/对照孔OD均值)×100％。细胞抑制率(％)＝100％-细胞存活率(％)。拟合函数求出抑制细胞生长达50％时的药物浓度(IC50)。实验重复三次。
3.实验结果
以上结果说明该类化合物能够广泛抑制各种肿瘤细胞的活性。附图2-8为本发明化合物DCZ0847对甲状腺癌(TPC-1细胞)、肺癌(A549细胞)、膀胱癌(T24细胞)、胃癌(SGC-7901细胞)、结肠癌细胞(HCT116细胞)、食管癌细胞(EC109细胞)、骨肉瘤细胞(U20S细胞)的抑制曲线。图中横坐标为化合物浓度(μM)，纵坐标为相对存活率(％)。
实施例3 针对多发性骨髓瘤的动物实验
1.实验材料
(1)细胞株：人多发性骨髓瘤细胞(ARP-1细胞)(美国ATCC，本实验室传代保存)，培养于1640培养基(含10％胎牛血清)。
(2)实验动物：雄性BALB/C裸鼠(5-6周，购自北京维通利华实验动物技术有限公司)，置于SPF级环境中饲养(上海第十人民医院中心实验室动物房)。
2.实验方法
(1)细胞培养具体参见测试例1。
(2)动物实验
将含2.5×106个ARP-1细胞悬浮于100μL预冷的磷酸盐缓冲盐(PBS)中并注射到裸鼠右腋窝皮下，当瘤子长成并可测量时，随机分至对照组和DCZ0847治疗组。DCZ0847治疗组裸鼠腹腔注射DCZ0847(10mg/kg，溶于1％DMSO和生理盐水，每周3次)，对照组裸鼠注射相同体积的溶剂(200μL，1％DMSO和生理盐水)。每两天称量小鼠体重，并测量肿瘤的长和宽，计算肿瘤体积(肿瘤体积＝(长×宽2)×0.5)。给药3周后处死老鼠并取肿瘤拍照。
3.实验结果
结果如图9所示，结果说明DCZ0847能够有效抑制裸鼠多发性骨髓瘤的生长。
实施例4 DCZ0847与硼替佐米联用能够有效抑制裸鼠体内多发性骨髓瘤的生长
1.实验材料
(1)细胞株：人多发性骨髓瘤细胞(ARP-1细胞)(美国ATCC，本实验室传代保存)，培养于1640培养基(含10％胎牛血清)。
(2)实验动物：雄性BALB/C裸鼠(5-6周，购自北京维通利华实验动物技术有限公司)，置于SPF级环境中饲养(上海第十人民医院中心实验室动物房)。
2.实验方法
(1)细胞培养具体参见测试例1。
(2)动物实验
将含2.5×106个ARP-1细胞悬浮于100μL预冷的PBS中并注射到裸鼠右腋窝皮下，当瘤子长成并可测量时，随机分为4组，分别为对照组、DCZ0847治疗组、硼替佐米治疗组及双药组。DCZ0847治疗组裸鼠腹腔注射DCZ0847(10mg/kg，溶于1％DMSO和生理盐水，每周3次)，硼替佐米治疗组裸鼠腹腔注射硼替佐米(1mg/kg，溶于1％DMSO和生理盐水,每周2次)，双药组裸鼠腹腔注射DCZ0847(10mg/kg)和硼替佐米(1mg/kg)，对照组裸鼠腹腔注射相同体积的溶剂(200μL，1％DMSO和生理盐水)。每两天称量小鼠体重，并测量肿瘤的长和宽，计算肿瘤体积(肿瘤体积＝(长×宽2)×0.5)。给药3周后处死老鼠并取肿瘤拍照。
3.实验结果
结果如图10所示，结果说明DCZ0847与硼替佐米联用能够有效抑制裸鼠多发性骨髓瘤的生长。
治疗多发性骨髓瘤药物组合物，所述组合物包含DCZ0847和硼替佐米，DCZ0847和硼替佐米质量比为10:1。所述的DCZ0847为10mg/kg，硼替佐米为1mg/kg。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员，在不脱离本发明方法的前提下，还可以做出若干改进和补充，这些改进和补充也应视为本发明的保护范围。
Claims (5)
1.一种抗肿瘤的化合物，其特征在于，所述肿瘤为多发性骨髓瘤、淋巴瘤、甲状腺癌、肺癌、膀胱癌、胃癌、结肠癌、食管癌或骨肉瘤；所述化合物的化学结构式如下：
2.权利要求1所述化合物的制备方法，其特征在于，包括以下步骤：
1）三氯氧磷溶于二氯甲烷，加入化合物1和三乙胺的二氯甲烷溶液，搅拌反应完全；2）反应液加入N-甲基哌嗪3和三乙胺的二氯甲烷溶液，搅拌反应完全；3）反应液加入化合物2、N,N-二甲胺基吡啶和三乙胺的二氯甲烷溶液，搅拌反应完全；4）加入水稀释，萃取，分离，水洗，饱和氯化钠洗，干燥，蒸干，硅胶柱分离，无色油状液体，加过量盐酸***溶解混匀，蒸干，既得目标化合物。
3.权利要求1所述化合物在制备药物中的应用，其特征在于，所述药物用于抗肿瘤，所述肿瘤为多发性骨髓瘤、淋巴瘤、甲状腺癌、肺癌、膀胱癌、胃癌、结肠癌、食管癌和骨肉瘤。
4.一种治疗多发性骨髓瘤药物组合物，所述组合物包含权利要求1所述的化合物和硼替佐米，所述的化合物和硼替佐米质量比为 10:1 。
5.权利要求4所述组合物在制备用于抑制肿瘤细胞的增殖疾病药物中的应用，所述的肿瘤为多发性骨髓瘤。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010116358.6A CN111285900B (zh) | 2020-02-25 | 2020-02-25 | 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010116358.6A CN111285900B (zh) | 2020-02-25 | 2020-02-25 | 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111285900A CN111285900A (zh) | 2020-06-16 |
| CN111285900B true CN111285900B (zh) | 2023-01-24 |
Family
ID=71023172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010116358.6A Expired - Fee Related CN111285900B (zh) | 2020-02-25 | 2020-02-25 | 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111285900B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107365265A (zh) * | 2016-05-12 | 2017-11-21 | 中国科学院上海药物研究所 | 夹竹桃麻素水溶性前药、其制备方法、药物组合物及用途 |
| CN109942630A (zh) * | 2019-02-28 | 2019-06-28 | 上海市第十人民医院 | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110268722A1 (en) * | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
-
2020
- 2020-02-25 CN CN202010116358.6A patent/CN111285900B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107365265A (zh) * | 2016-05-12 | 2017-11-21 | 中国科学院上海药物研究所 | 夹竹桃麻素水溶性前药、其制备方法、药物组合物及用途 |
| CN109942630A (zh) * | 2019-02-28 | 2019-06-28 | 上海市第十人民医院 | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 |
Non-Patent Citations (4)
| Title |
|---|
| A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib;Gege Chen，et al.;《CANCER LETTERS》;20201231;第478卷;第45-55页 * |
| Drug‐like dietary vanilloids induce anticancer activity through proliferation inhibition and regulation of bcl‐related apoptotic proteins;Chun‐Wai Mai，et al.;《Phytotherapy Research.》;20181231;第32卷;第1108-1118页 * |
| Synthesis and Characterization of Phosphoramide Piperazine Analogues of Paeonol;Xu Li，et al.;《Phosphorus, Sulfur, and Silicon and the Related Elements》;20150309;第1-14页 * |
| 罗布麻宁治疗少弱***症模型小鼠的作用机制;马宝良 等;《中华男科学杂志》;20160731;第22卷(第7期);第649-653页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111285900A (zh) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8722698B2 (en) | Berbamine derivatives | |
| CN107382966B (zh) | 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途 | |
| CN101812059B (zh) | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 | |
| US20140235568A1 (en) | Gemcitabine amide derivative and preparation method and use thereof | |
| EP4108666A1 (en) | Multi-target tyrosine kinase inhibitor | |
| JP2017534657A (ja) | 新型シチジン誘導体およびその適用 | |
| WO2015096640A1 (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
| CN109942630B (zh) | 基于柳胺酚和紫檀芪的天然活性分子偶联化合物及其用途 | |
| CN108148098B (zh) | 靶向癌细胞高水平ros的吉西他滨-芳香氮芥缀合物及其制备方法和医药用途 | |
| AU2006308849A1 (en) | Diazonamide a analog | |
| CN111285900B (zh) | 基于紫檀芪和香荚兰乙酮的偶联分子dcz0847类化合物、其制备方法及用途 | |
| US10351586B2 (en) | Cytidine derivative dimers and applications thereof | |
| EP3470403B1 (en) | Taxoid compound and preparation method and use thereof | |
| CN112442062B (zh) | 一种柳胺酚有机硅化合物及抗肿瘤用途 | |
| AU2020333099B2 (en) | A prodrug platform useful to deliver amines, amides and phenols | |
| JP7180923B2 (ja) | 白金系化合物リン酸塩及びその製造方法 | |
| CN108299390B (zh) | 抗肿瘤化合物dcz0415及其制备方法和应用 | |
| CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
| CN105037490B (zh) | 一类乙二醛酶i不可逆抑制剂及其制备方法和用途 | |
| WO2014193696A2 (en) | Benzimidazole carboxylic acid derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| CN117700419A (zh) | 一氧化氮供体型咔唑衍生物及其在***疾病中的用途 | |
| CN115974890A (zh) | 石蒜碱衍生物及其制备方法和在制备抗肿瘤药物中的应用 | |
| CN116251107A (zh) | Z-2-366在用于制备抑制eEF2K表达的药物中的应用 | |
| CN102417514B (zh) | 吡啶衍生物、其制备方法和用途 | |
| RU2006125082A (ru) | Производные пролина, используемые как фармацевтически активные ингредиенты для лечения опухолей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20230124 |